Published in Eur Urol on January 01, 1990
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol Pharmacol (2003) 1.65
Enantiomer selective glucuronidation of the non-steroidal pure anti-androgen bicalutamide by human liver and kidney: role of the human UDP-glucuronosyltransferase (UGT)1A9 enzyme. Basic Clin Pharmacol Toxicol (2013) 0.81
Controversies in the management of advanced prostate cancer. Br J Cancer (1999) 0.76
The pharmacokinetics of Casodex enantiomers in subjects with impaired liver function. Br J Clin Pharmacol (1993) 0.75
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol (2001) 5.17
Bladder trauma in the long-distance runner: "10,000 metres haematuria". Br J Urol (1977) 2.99
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer (2003) 2.38
European Code Against Cancer and scientific justification: third version (2003). Ann Oncol (2003) 2.17
The TNM classification of prostate cancer. Prostate Suppl (1992) 1.96
High pressure chronic retention. Br Med J (Clin Res Ed) (1983) 1.70
Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms. Lancet (1983) 1.69
Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer (1995) 1.58
TNM classification of genitourinary tumours 1987--position of the EORTC Genitourinary Group. Br J Urol (1988) 1.55
The response of prostatic fluid pH in inflammation. Br J Urol (1974) 1.37
Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone. Eur Urol (1982) 1.35
Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group. Cancer (1990) 1.24
The association of benign prostatic hyperplasia and cancer of the prostate. Cancer (1992) 1.22
Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group. J Urol (1983) 1.11
Myocardial infarction and nicotine patch: a contributing or causative factor? Eur Heart J (1993) 1.09
Photodynamic therapy for localised prostatic cancer: light penetration in the human prostate gland. J Urol (1990) 1.08
Experience wiht vasovasostomy: operative technique and results. Br J Urol (1979) 1.06
In vivo laser light distribution in human prostatic carcinoma. J Urol (1994) 1.05
The effect of cellulose phosphate on intestinal absorption and urinary excretion of calcium. Some experience in its use in the treatment of calcium stone formation. Br J Urol (1974) 1.03
World Health Organization Consensus Committee recommendations concerning the diagnosis of BPH. Prog Urol (1991) 1.01
Chemoresection in Ta-T1 bladder cancer. Members of the EORTC Genito-Urinary Group. Eur Urol (1996) 1.01
Asymptomatic nephrocutaneous fistula: a report of 2 cases. J Urol (1988) 0.99
Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer. Clin Pharmacokinet (1998) 0.97
Quality of life and treatment of hormone resistant metastatic prostatic cancer. The EORTC Genito-Urinary Group. Eur J Cancer (1990) 0.97
Anatomical factors in prostatitis. Br J Urol (1974) 0.96
The impact of supportive nursing care on the needs of men with prostate cancer: a study across seven European countries. Br J Cancer (2013) 0.93
The role of magnesium in calcium oxalate urolithiasis. Br J Urol (1988) 0.93
Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol (Oxf) (1994) 0.92
Prostatodynia--physiological characteristics and rational management with muscle relaxants. Br J Urol (1981) 0.91
Identification of Belgian mosquito species (Diptera: Culicidae) by DNA barcoding. Mol Ecol Resour (2014) 0.90
Practical management of patients with dilated upper tracts and chronic retention of urine. Br J Urol (1984) 0.90
Incidence of renal stones in 18 British towns. A collaborative study. Br J Urol (1987) 0.89
Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J Urol (1987) 0.88
Regional variation of cytosol androgen receptors throughout the diseased human prostate gland. Prostate (1986) 0.88
Reversal of vasectomy. Int J Gynaecol Obstet (1980) 0.88
Optimization of multifiber light delivery for the photodynamic therapy of localized prostate cancer. Photochem Photobiol (1993) 0.88
Management of relapsing disease in prostate cancer. Cancer (1992) 0.87
Computed tomography and transrectal ultrasound in the diagnosis of prostatic disease--a comparative study. Br J Urol (1983) 0.86
The pharmacokinetics of Casodex in laboratory animals. Xenobiotica (1991) 0.86
International Consultation on Urological Diseases: a decade of progress. Prostate (2000) 0.86
Distribution of the immunoglobulins G, A and M in the prostatic fluid of patients with prostatitis. Clin Chim Acta (1974) 0.86
Catheters and urethral strictures. Br J Urol (1986) 0.86
The clinical presentation of Chlamydia trachomatis in a urological practice. Br J Urol (1985) 0.86
The effect of food on the pharmacokinetics of the bicalutamide ('Casodex') enantiomers. Biopharm Drug Dispos (1997) 0.86
Anaphylactic reactions to repeated intravesical instillation with cisplatin. Lancet (1983) 0.85
The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical trial 30853. Eur J Cancer (1996) 0.84
Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86. Cancer (1990) 0.84
Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer. Br Med J (Clin Res Ed) (1985) 0.84
Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. Prostate (1998) 0.84
Ketoconazole and liarozole in the treatment of advanced prostatic cancer. Cancer (1993) 0.84
The European Organization for Research on Treatment of Cancer. Genito-urinary Tract Cancer Cooperative Group. Acta Urol Belg (1980) 0.84
Effects of ovariectomy and steroid treatment on hypophyseal sensitivity to purified LH-releasing factor (LRF). Endocrinology (1974) 0.83
Restaging procedures, criteria of response, and relationship between pathological response and survival. Semin Oncol (1990) 0.83
A comparison of serum kinetics and tissue distribution of photofrin II following intravenous and intraperitoneal injection in the mouse. Photochem Photobiol (1989) 0.83
Phytoestrogens and diseases of the prostate gland. Baillieres Clin Endocrinol Metab (1998) 0.83
Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group. Urology (1998) 0.83
The pattern of urolithiasis in the Royal Navy. J R Nav Med Serv (1965) 0.82
Quality of life in patients with prostatic cancer. A feasibility study. The Members of Quality of Life Committee of the EORTC Genitourinary Group. Cancer (1993) 0.82
Urogastrone-epidermal growth factor concentrations in prostatic fluid of normal individuals and patients with benign prostatic hypertrophy. Clin Sci (Lond) (1986) 0.82
Enantioselective metabolism and pharmacokinetics of Casodex in the male rat. Xenobiotica (1995) 0.82
Spatial and seasonal variability of sediment oxygen consumption and nutrient fluxes at the sediment water interface in a sub-tropical lagoon (New Caledonia). Mar Pollut Bull (2010) 0.82
Effects of magnesium on calcium oxalate crystallization. J Urol (1985) 0.81
Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer. Cancer (1990) 0.81
An investment appraisal of alternative technologies for the treatment of stones in the kidney and ureter. Community Med (1986) 0.81
The effect of glycosaminoglycans on the crystallisation of calcium oxalate. Br J Urol (1989) 0.80
Prostatic intraepithelial neoplasia: the preinvasive stage of prostate cancer. Overview of the prostate committee report. Scand J Urol Nephrol Suppl (2000) 0.80
Tuberculous stricture of ureter. A new method of intubated ureterotomy. Br J Urol (1986) 0.80
The European Randomized Study of Screening for Prostate Cancer: an update. Cancer (1997) 0.79
Anti-estrogens in the treatment of prostatic cancer. Acta Urol Belg (1980) 0.79
Surgery or radiation: is there really a choice for early prostate cancer. Crit Rev Oncol Hematol (1998) 0.79
Radiation dose to patient and staff during percutaneous nephrostolithotomy. Br J Urol (1987) 0.79
The ultrastructure of Rhesus monkey prostate. Urol Res (1977) 0.79
Bladder trauma in the long-distance runner. Am J Sports Med (1979) 0.79
The role of Chlamydia trachomatis in epididymitis. Br J Urol (1987) 0.79
Differential androgen uptake by the lobes of the rhesus monkey prostate. Br J Urol (1977) 0.79
Effects of high-dose ketoconazole and dexamethasone on ACTH-stimulated adrenal steroidogenesis in orchiectomized prostatic cancer patients. Acta Endocrinol (Copenh) (1987) 0.79
[Pneumonitis following amiodarone therapy]. J Belge Radiol (1989) 0.78
Consequences of vasectomy: an immunological and histological study related to subsequent fertility. Br J Urol (1979) 0.78
Genetic and hematological studies in a group of 114 adult patients with SC sickle cell disease. Am J Hematol (1998) 0.78
The zonal anatomy of the prostate in man and in the rhesus monkey (Macaca mulatta). Urol Res (1977) 0.78
The advantages of 99mTc DTPA(Sn) in dynamic renal scintigraphy and measurement of renal function. Br J Urol (1980) 0.78
Prostatic cancer. Urol Res (1977) 0.78
The value of the bone scan. Prog Clin Biol Res (1990) 0.78
Phase I trial of high-dose fosfestrol in hormone-refractory adenocarcinoma of the prostate. Prostate (1994) 0.78
Possible relationship between dietary factors and pathogenesis of prostate cancer. Int J Urol (1998) 0.78
Do stone formers have lower urinary fibrinolytic activity than controls? Br J Urol (1990) 0.78
Vincristine in advanced bladder cancer: a European organization for research on treatment of cancer (EORTC) phase II study. Cancer Treat Rep (1983) 0.78
Vehicle effects on skin sensitizing potency of four chemicals: assessment using the local lymph node assay. Int J Cosmet Sci (2001) 0.77
ERSPC: features and preliminary results from the Antwerp study centre. BJU Int (2003) 0.77
The morphology of the parenchyma of the prostate. Urol Res (1977) 0.77
Can dietary factors influence prostatic disease? BJU Int (1999) 0.77
The determination of platinum in biological fluid by means of graphite furnace atomic absorption spectrometry. Clin Chim Acta (1981) 0.77
Lack of immunogenicity of ice structuring protein type III HPLC12 preparation administered by the oral route to human volunteers. Food Chem Toxicol (2006) 0.77